Patents Assigned to MedImmune, LLC
-
Patent number: 11447542Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O2 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae) and/or protects mice from a lethal Klebsiella challenge. The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O2 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: GrantFiled: August 4, 2017Date of Patent: September 20, 2022Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SAInventors: Qun Wang, Charles K. Stover, Meghan Pennini, Xiaodong Xiao, Davide Corti, Elisabetta Cameroni, Martina Beltramello, Gilad Kaplan, Anna DeMarco
-
Patent number: 11414477Abstract: The present disclosure relates to a process for preparing antibodies with a defined glycosylation pattern, in particular antibodies with a glycan terminating in an N-acetylglucosamine. The antibodies of the disclosure are suitable for use in a process to conjugate a payload thereto. The disclosure also extends to molecules obtained and obtainable from the process disclosed herein, novel molecules and intermediates, compositions comprising said molecules and uses of the molecules and compositions, particularly in treatment, for example in the treatment of cancer.Type: GrantFiled: January 26, 2017Date of Patent: August 16, 2022Assignee: MedImmune, LLCInventors: Changshou Gao, Pamela Thompson, Dorin Toader, Nazzareno Dimasi
-
Patent number: 11305012Abstract: Provided herein are antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life, as well as compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.Type: GrantFiled: September 23, 2014Date of Patent: April 19, 2022Assignee: MedImmune, LLCInventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto, Andrew Pierce
-
Patent number: 11279759Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: September 13, 2019Date of Patent: March 22, 2022Assignee: MedImmune, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
-
Patent number: 11220541Abstract: The present invention relates to the use of the Chemokine (C—C motif) ligand 20 (CCL20) as a biomarker to stratify or identify populations of patients suffering from interleukin-23 (IL23)-mediated diseases (e.g., Crohn's disease) responsive to treatment with an, anti-IL23 antagonist (including, e.g., anti-IL23 antibodies). Levels of CCL20 above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent, (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent. CCL20 can be used in combination with other IL23 pathway biomarkers such as IL22 and/or lipocalin-2 (LCN2).Type: GrantFiled: December 16, 2016Date of Patent: January 11, 2022Assignees: AMGEN INC., MEDIMMUNE, LLCInventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, Jr.
-
Patent number: 11186628Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.Type: GrantFiled: May 1, 2020Date of Patent: November 30, 2021Assignee: MEDIMMUNE, LLCInventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
-
Patent number: 11186627Abstract: The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus. In one embodiment, an antibody or binding fragment according to the invention is capable of binding to and/or neutralizing one or more influenza A virus group 1 subtypes selected from H1, H2, H5, H6, H8, H9, H11, H12, H13, H16 and H17 and variants thereof and one or more influenza A virus group 2 subtype selected from H3, H4, H7, H1, 0, H14 and H15 and variants thereof.Type: GrantFiled: October 8, 2019Date of Patent: November 30, 2021Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SAInventors: Ebony Benjamin, Nicole Kallewaard-LeLay, Josephine Mary McAuliffe, Frances Palmer-Hill, Leslie Wachter, Andy Yuan, Qing Zhu, Davide Corti, Antonio Lanzavecchia, Barbara Guarino, Anna DeMarco
-
Patent number: 11174304Abstract: The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.Type: GrantFiled: November 7, 2019Date of Patent: November 16, 2021Assignees: MEDIMMUNE, LLC, HUMABS BIOMED SAInventors: Nicole Kallewaard-Lelay, Qing Zhu, Ebony Benjamin, Leslie Wachter, Andy Yuan, Josephine Mary McAuliffe, Davide Corti, Antonio Lanzavecchia
-
Patent number: 11168133Abstract: The present disclosure is directed to anti-Staphylococcus aureus antibody combinations including combinations of antibodies that bind to S. aureus alpha toxin (AT) protein, clumping factor A protein (ClfA), and/or at least one leukotoxin protein. Methods of treating and preventing infections comprising administering the antibody combinations are also provided herein.Type: GrantFiled: October 8, 2019Date of Patent: November 9, 2021Assignee: MedImmune, LLCInventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Taylor Cohen
-
Patent number: 11155606Abstract: The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to a Staphylococcus aureus clumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating a Staphylococcus aureus infection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds to S. aureus alpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.Type: GrantFiled: July 24, 2019Date of Patent: October 26, 2021Assignees: MedImmune, LLC, Humabs BioMed SAInventors: Christine Tkaczyk, Bret Sellman, Martin Borrok, III, Davide Corti, Andrea Minola
-
Patent number: 11117956Abstract: The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae O1 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or preventing Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising administering the Klebsiella pneumoniae O1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.Type: GrantFiled: October 16, 2017Date of Patent: September 14, 2021Assignees: MedImmune, LLC, Humabs BioMed SAInventors: Qun Wang, Charles Stover, Meghan Pennini, Chew-shun Chang, Xiaodong Xiao, Jamese Hilliard, Gilad Kaplan, Davide Corti, Elisabetta Cameroni, Martina Beltramello
-
Patent number: 11098289Abstract: Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.Type: GrantFiled: May 13, 2016Date of Patent: August 24, 2021Assignee: MedImmune, LLCInventors: Manuel Baca, Andrew C. Nyborg
-
Patent number: 11077254Abstract: A smart plunger rod adapted to push a medication out of a syringe is disclosed. The plunger rod comprises a shaft sized and dimensioned to act on a piston on the syringe and a finger actuated head portion containing at least two subunits of a wireless sensor. In a pre-activation configuration, the subunits are spaced apart from each other by a physical barrier and the wireless sensor is non-operational. In a post-activation configuration, the subunits are connected to each other and the sensor is operational to send a signal. A user activates the finger actuated head portion to reversibly move the physical barrier and moves the plunger rod from the pre-activation configuration to the post-activation configuration. The signal sent by the sensor comprises information relating to ejecting the medication out of the syringe, and is received by a remote receiver.Type: GrantFiled: December 13, 2017Date of Patent: August 3, 2021Assignee: MEDIMMUNE, LLCInventors: Janardhanan Anand Subramony, Michael C. Song
-
Patent number: 11059884Abstract: The present disclosure is directed to leukotoxin-binding antibodies and antigen-binding fragments thereof. The antibodies and fragments can be used, for example, to detect leukotoxin and/or in methods of treating and preventing Staphylococcus aureus infections.Type: GrantFiled: October 8, 2019Date of Patent: July 13, 2021Assignees: MedImmune, LLC, Humabs BioMed SAInventors: Christine Tkaczyk, Bret Sellman, Qun Du, Melissa Damschroder, Davide Corti, Andrea Minola
-
Patent number: 11016099Abstract: The present invention relates to the use of components of the IL23 pathway as biomarkers, e.g., IL22, LCN2 and combinations thereof, to stratify or identify populations of patients suffering from IL23-mediated diseases (e.g., Crohn's disease) responsive to treatment with an anti-IL23 antagonist (including, e.g., anti-IL23 antibodies or antigen-binding fragments thereof). Levels of IL23 pathway biomarkers above or below a predetermined threshold can be used, for example, (i) to determine whether a patient with an IL23-mediated disease or disorder such a Crohn's disease is eligible or non-eligible for treatment with a therapeutic agent (e.g., an ant-IL23 antibody), (ii) to determine whether treatment with a certain agent should be commenced, suspended, or modified, (iii) to diagnose whether the IL23-mediated disease is treatable or not treatable with a specific therapeutic agent, or (iv) to predict the outcome of treating the IL23-mediated disease with a specific therapeutic agent.Type: GrantFiled: September 16, 2016Date of Patent: May 25, 2021Assignees: AMGEN INC., MEDIMMUNE, LLCInventors: Robert W. Georgantas, III, Chris Morehouse, Brandon Higgs, Koustubh Ranade, Katie Streicher, William Rees, Meina Liang, Raffaella Faggioni, Jing Li, Inna Vainshtein, Yen-Wah Lee, Jingjing Chen, Robert A. Gasser, Jr.
-
Patent number: 10988546Abstract: The disclosure is directed to an antibody-drug conjugate (ADC) comprising a monoclonal antibody, or an antigen-binding fragment thereof, directed against B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The disclosure also provides compositions comprising the antibody-drug conjugate and methods of killing multiple myeloma cells (including multiple myeloma stems cells) that express BCMA by contacting multiple myeloma cells with the ADC.Type: GrantFiled: July 31, 2018Date of Patent: April 27, 2021Assignee: MedImmune, LLCInventors: Krista Kinneer, Reena Varkey, Xiaodong Xiao, Elaine M. Hurt, David Tice
-
Patent number: 10975155Abstract: Provided herein is a CD40L-Fc fusion protein and methods of using the fusion protein in the treatment of cancer comprising administering the CD40L-Fc fusion protein or the CD40L-Fc fusion protein in combination with one or more immune checkpoint inhibitors (e.g., an anti-CTLA4 antibody, anti-PD-L1 antibody).Type: GrantFiled: May 12, 2017Date of Patent: April 13, 2021Assignee: MEDIMMUNE, LLCInventors: Manuel Baca, Stacey Drabic, Peter Emtage, Ronald Herbst
-
Patent number: 10883087Abstract: Described are improved uricase sequences having beneficial effects and methods of treating patients suffering from hyperuricemia.Type: GrantFiled: October 23, 2018Date of Patent: January 5, 2021Assignee: MedImmune, LLCInventors: Manuel Baca, Andrew C. Nyborg
-
Patent number: 10882897Abstract: Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.Type: GrantFiled: September 4, 2019Date of Patent: January 5, 2021Assignee: MEDIMMUNE, LLCInventors: Nicole Kallewaard-Lelay, Qing Zhu, Godfrey Jonah Rainey, Cuihua Gao, Srinath Kasturirangan, Changshou Gao
-
Publication number: 20200407429Abstract: Antibodies and antigen binding fragments thereof directed against Staphylococcus aureus (S. aureus) surface determinant antigens and secreted toxins are disclosed. Methods of detecting, diagnosing and treating S. aureus using the antibodies and antigen binding fragments thereof are also provided.Type: ApplicationFiled: July 9, 2020Publication date: December 31, 2020Applicant: MedImmune, LLCInventors: Bret SELLMAN, Christine Tkaczyk, Partha S. Chowdhury, Lei Hua, Peter Pavlik, Rebecca Buonpane, Chew-Shun Chang